[HTML][HTML] Beyond taxanes: the next generation of microtubule-targeting agents
J Cortes, M Vidal - Breast cancer research and treatment, 2012 - Springer
Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
[PDF][PDF] Beyond taxanes: the next generation of microtubule-targeting agents
J Cortes, M Vidal - Breast Cancer Res Treat, 2012 - researchgate.net
Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
[HTML][HTML] Beyond taxanes: the next generation of microtubule-targeting agents
J Cortes, M Vidal - Breast Cancer Research and Treatment, 2012 - ncbi.nlm.nih.gov
Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
[PDF][PDF] Beyond taxanes: the next generation of microtubule-targeting agents
J Cortes, M Vidal - Breast Cancer Res Treat, 2012 - core.ac.uk
Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
Beyond taxanes: the next generation of microtubule-targeting agents
J Cortes, M Vidal - Breast Cancer Research and Treatment, 2012 - search.proquest.com
Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
Beyond taxanes: the next generation of microtubule-targeting agents.
J Cortes, M Vidal - Breast Cancer Research and Treatment, 2011 - europepmc.org
Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
Beyond taxanes: the next generation of microtubule-targeting agents
J Cortes, M Vidal - Breast Cancer Research and Treatment, 2012 - infona.pl
Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
[引用][C] Beyond taxanes: the next generation of microtubule-targeting agents
J Cortes, M Vidal - Breast Cancer Research and Treatment, 2011 - cir.nii.ac.jp
Beyond taxanes: the next generation of microtubule-targeting agents | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[PDF][PDF] Beyond taxanes: the next generation of microtubule-targeting agents
J Cortes, M Vidal - Breast Cancer Res Treat, 2012 - cyberleninka.org
Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
Beyond taxanes: the next generation of microtubule-targeting agents
J Cortes, M Vidal - Breast cancer research and treatment, 2012 - pubmed.ncbi.nlm.nih.gov
Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility
may be limited by primary or acquired resistance. New microtubule-targeting agents have …
may be limited by primary or acquired resistance. New microtubule-targeting agents have …